Bilirubin Levels to Diagnose Appendicitis and Predict Appendiceal Perforation
Predictors of Appendiceal Perforation and the Role of Total Bilirubin at Presentation: A Single Center Prospective Cross-sectional Study in Nepal
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
Bagmati
-
Kathmandu, Bagmati, Nepal, 44620
- Shree Birendra Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients of age group above 5 years with acute appendicitis undergoing appendectomy with written informed consent.
Exclusion Criteria:
- Patients with appendicular lump.
- Patients with acute and chronic liver diseases like acute hepatitis, hemolytic disease, Gilbert's syndrome, Dubin-Johnson syndrome, alcoholic liver disease.
- Acquired or Congenital Biliary Disease.
- History of Hepatotoxic drugs.
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Patients of age group above 5 years with acute appendicitis undergoing appendectomy
Patients of age group above 5 years with acute appendicitis undergoing appendectomy, without acute or chronic liver diseases, acquired or congenital bilirary diseases, history of use of hepatotoxic drugs or diagnosis of appendicular lump
|
Non-interventional study
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Perforated appendix
Time Frame: Presentation to hospital till perioperative period
|
Perforated appendicitis was confirmed intraoperatively by the surgeon and at histological analysis of the specimen by the rupture of appendiceal wall to the serosa.
Those with gangrenous walls were also taken as perforated.
|
Presentation to hospital till perioperative period
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Chair: Bhairav Kumar Hamal, MS, Fellow - Urosurgery, Nepalese Army Institute of Health Sciences
Publications and helpful links
General Publications
- Sand M, Bechara FG, Holland-Letz T, Sand D, Mehnert G, Mann B. Diagnostic value of hyperbilirubinemia as a predictive factor for appendiceal perforation in acute appendicitis. Am J Surg. 2009 Aug;198(2):193-8. doi: 10.1016/j.amjsurg.2008.08.026. Epub 2009 Mar 23.
- Sirikurnpiboon S, Amornpornchareon S. Factors Associated with Perforated Appendicitis in Elderly Patients in a Tertiary Care Hospital. Surg Res Pract. 2015;2015:847681. doi: 10.1155/2015/847681. Epub 2015 Aug 24.
- Potey K, Kandi A, Jadhav S, Gowda V. Study of outcomes of perforated appendicitis in adults: a prospective cohort study. Ann Med Surg (Lond). 2023 Mar 16;85(4):694-700. doi: 10.1097/MS9.0000000000000277. eCollection 2023 Apr.
- Chaudhary P, Kumar A, Saxena N, Biswal UC. Hyperbilirubinemia as a predictor of gangrenous/perforated appendicitis: a prospective study. Ann Gastroenterol. 2013;26(4):325-331.
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- IRB604
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.